Best Practice & Research Clinical Rheumatology
Volume 20, Issue 6 , Pages 1119-1137 , December 2006

Reactive arthritis

  • Andreas Klos, MD (Specialist and Senior Lecturer for Medical Microbiology, Vice-Chairman of the Department)
  • Lars Köhler, MD (Specialist and Senior Lecturer for Rheumatology)
  • Jens G. Kuipers, MD (Specialist and Senior Lecturer for Rheumatology, Chief of the Department)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 421 5599511; Fax: +49 421 5599376.

References 

  1. Reiter H. Über eine bisher unbekannte Spirochäteninfektion (Spirochaetosis arthritica). Deutsche Medizinische Wochenschrift. 1916;42:1535–1536
  2. Ahvonen P, Sievers K, Aho K. Arthritis associated with Yersinia enterocolitica infection. Acta Rheumatologica Scandinavica. 1969;15:232–253
  3. Aho K, Ahvonen P, Lassus A, et al. HL-A antigen 27 and reactive arthritis. Lancet. 1973;2:157–161
  4. Kvien TK, Glennas A, Melby G, et al. Reactive arthritis: incidence, triggering agents and clinical presentation. The Journal of Rheumatology. 1994;21:115–122
  5. Toivanen A, Toivanen P. Reactive arthritis. Best Practice and Research Clinical Rheumatology. 2004;18:689–703
  6. Gaston JSH, Lillicrap MS. Arthritis associated with enteric infection. Best Practice and Research Clinical Rheumatology. 2003;17:219–239
  7. Zeidler H, Kuipers J, Köhler L. Chlamydia-induced arthritis. Current Opinion in Rheumatology. 2004;16:380–392
  8. Yu D, Kuipers JG. Role of bacteria and HLA-B27 in the pathogenesis of reactive arthritis. Rheumatic Diseases Clinics of North America. 2003;29:21–36
  9. Leirisalo M, Skylv G, Kousa M, et al. Followup study on patients with Reiter's disease and reactive arthritis, with special reference to HLA-B27. Arthritis and Rheumatism. 1982;25:249–259
  10. Hogan RJ, Mathews SA, Mukhopadhyay S, et al. Chlamydial persistence: beyond the biphasic paradigm. Infection and Immunity. 2004;72:1843–1855
  11. Kuipers JG, Zeidler H, Köhler L. How does Chlamydia cause arthritis?. Rheumatic Diseases Clinics of North America. 2003;29:613–629
  12. Granfors K, Merilahti-Palo R, Luukkainen R, et al. Persistence of yersinia antigens in peripheral blood cells from patients with Yersinia enterocolitica O:3 infection with or without reactive arthritis. Arthritis and Rheumatism. 1998;41:855–862
  13. Cox CJ, Kempsell KE, Gaston JSH. Investigation of infectious agents associated with arthritis by reverse transcription PCR of bacterial rRNA. Arthritis Research and Therapy. 2003;5:R1–R8[Epub 2002 Oct 11]
  14. Nanagara R, Li F, Beutler A, et al. Alteration of Chlamydia trachomatis biologic behavior in synovial membranes. Suppression of surface antigen production in reactive arthritis and Reiter's syndrome. Arthritis and Rheumatism. 1995;38:1410–1417
  15. Gerard HC, Branigan PJ, Schumacher HR, Hudson AP. Synovial Chlamydia trachomatis in patients with reactive arthritis/Reiter's syndrome are viable but show aberrant gene expression. The Journal of Rheumatology. 1998;25:734–742
  16. Gerard HC, Whittum-Hudson JA, Schumacher HR, Hudson AP. Synovial Chlamydia trachomatis up-regulates expression of a panel of genes similar to that transcribed by Mycobacterium tuberculosis during persistent infection. Annals of the Rheumatic Diseases. 2006;65:321–327
  17. Clements MO, Eriksson S, Thompson A, et al. Polynucleotide phosphorylase is a global regulator of virulence and persistency in Salmonella enterica. Proceedings of the National Academy of Sciences U S A. 2002;99:8784–8789
  18. Bohn E, Müller S, Lauber J, et al. Gene expression patterns of epithelial cells modulated by pathogenicity factors of Yersinia enterocolitica. Cellular Microbiology. 2003;6:129–141
  19. Sassetti CM, Rubin EJ. Genetic requirements for mycobacterial survival during infection. Proceedings of the National Academy of Sciences U S A. 2003;100:12989–12994
  20. Da Costa CU, Wantia N, Kirschning CJ, et al. Heat shock protein 60 from Chlamydia pneumoniae elicits an unusual set of inflammatory responses via Toll-like receptor 2 and 4 in vivo. European Journal of Immunology. 2004;34:2874–2884
  21. Darville T, O'Neill JM, Andrews CW, et al. Toll-like receptor-2, but not Toll-like receptor-4, is essential for development of oviduct pathology in chlamydial genital tract infection. Journal of Immunology. 2003;171:6187–6197
  22. Hess S, Rheinheimer C, Tidow F, et al. The reprogrammed host: Chlamydia trachomatis-induced up-regulation of glycoprotein 130 cytokines, transcription factors, and antiapoptotic genes. Arthritis and Rheumatism. 2001;44:2392–2401
  23. Hess S, Peters J, Bartling G, et al. More than just innate immunity: comparative analysis of Chlamydophila pneumoniae and Chlamydia trachomatis effects on host-cell gene regulation. Cellular Microbiology. 2003;5:785–795
  24. Yamamoto T, Sashinami H, Takaya A, et al. Disruption of the Genes for ClpXP Protease of Salmonella enterica serovar typhimurium results in persistent infection in mice, and development of persistence requires endogenous gamma interferon and tumor necrosis factor alpha. Infection and Immunity. 2001;69:3164–3174
  25. Hoffmann R, van Erp K, Trülzsch K, Heesemann J. Transcriptional responses of murine macrophages to infection with Yersinia enterocolitica. Cellular Microbiology. 2003;6:377–390
  26. Fan T, Lu H, Hu H, et al. Inhibition of apoptosis in chlamydia-infected cells: blockade of mitochondrial cytochrome c release and caspase activation. The Journal of Experimental Medicine. 1998;187:487–496
  27. Fischer SF, Vier J, Kirschnek S, et al. Chlamydia inhibit host cell apoptosis by degradation of proapoptotic BH3-only proteins. The Journal of Experimental Medicine. 2004;200:905–916
  28. Zhong G, Fan P, Ji H, et al. Identification of a chlamydial protease-like activity factor responsible for the degradation of host transcription factors. The Journal of Experimental Medicine. 2001;193:935–942
  29. Gaston JS, Deane KH, Jecock RM, Pearce JH. Identification of 2 Chlamydia trachomatis antigens recognized by synovial fluid T cells from patients with Chlamydia induced reactive arthritis. The Journal of Rheumatology. 1996;23:130–136
  30. Matyszak MK, Young JL, Gaston JS. Uptake and processing of Chlamydia trachomatis by human dendritic cells. European Journal of Immunology. 2002;32:742–751
  31. Mertz AK, Ugrinovic S, Lauster R, et al. Characterization of the synovial T cell response to various recombinant Yersinia antigens in Yersinia enterocolitica-triggered reactive arthritis. Heat-shock protein 60 drives a major immune response. Arthritis and Rheumatism. 1998;41:315–326
  32. Baeten D, Van Damme N, Van den Bosch F, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. Annals of the Rheumatic Diseases. 2001;60:750–755
  33. Zou J, Rudwaleit M, Brandt J, et al. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis and Rheumatism. 2003;48:780–790
  34. Baeten D, Vandooren B, De Rycke L, et al. Effect of infliximab treatment on T cell cytokine responses in spondylarthropathy: comment on the article by Zou et al. Arthritis and Rheumatism. 2004;50:1015–1016
  35. Yin Z, Braun J, Neure L, et al. Crucial role of interleukin-10/interleukin-12 balance in the regulation of the type 2 T helper cytokine response in reactive arthritis. Arthritis and Rheumatism. 1997;40:1788–1797
  36. Schlaak J, Hermann E, Ringhoffer M, et al. Predominance of Th1-type T cells in synovial fluid of patients with Yersinia-induced reactive arthritis. European Journal of Immunology. 1992;22:2771–2776
  37. Lahesmaa R, Yssel H, Batsford S, et al. Yersinia enterocolitica activates a T helper type 1-like T cell subset in reactive arthritis. Journal of Immunology. 1992;148:3079–3085
  38. Simon AK, Seipelt E, Wu P, et al. Analysis of cytokine profiles in synovial T cell clones from chlamydial reactive arthritis patients: predominance of the Th1 subset. Clinical and Experimental Immunology. 1993;94:122–126
  39. Rihl M, Gu J, Baeten D, et al. Alpha beta but not gamma delta T cell clones in synovial fluids of patients with reactive arthritis show active transcription of tumour necrosis factor alpha and interferon gamma. Annals of the Rheumatic Diseases. 2004;63:1673–1676
  40. Hermann E, Yu DT, Meyer zum Buschenfelde KH, Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet. 1993;342:646–650
  41. Duchmann R, May E, Ackermann B, et al. HLA-B27-restricted cytotoxic T lymphocyte responses to arthritogenic enterobacteria or self-antigens are dominated by closely related TCRBV gene segments. A study in patients with reactive arthritis. Scandinavian Journal of Immunology. 1996;43:101–108
  42. Dulphy N, Peyrat MA, Tieng V, et al. Common intra-articular T cell expansions in patients with reactive arthritis: identical beta-chain junctional sequences and cytotoxicity toward HLA-B27. Journal of Immunology. 1999;162:3830–3839
  43. Kapasi K, Inman RD. HLA-B27 expression modulates gram-negative bacterial invasion into transfected L cells. Journal of Immunology. 1992;148:3554–3559
  44. Ortiz-Alvarez O, Yu DT, Petty RE, Finlay BB. HLA-B27 does not affect invasion of arthritogenic bacteria into human cells. Journal of Rheumatology. 1998;25:1765–1771
  45. Laitio P, Virtala M, Salmi M, et al. HLA-B27 modulates intracellular survival of Salmonella enteritidis in human monocytic cells. European Journal of Immunology. 1997;27:1331–1338
  46. Taurog JD, Maika SD, Satumtira N, et al. Inflammatory disease in HLA-B27 transgenic rats. Immunological Reviews. 1999;169:209–223
  47. Khare SD, Hansen J, Luthra HS, David CS. HLA-B27 heavy chains contribute to spontaneous inflammatory disease in B27/human beta2-microglobulin (beta2m) double transgenic mice with disrupted mouse beta2m. The Journal of Clinical Investigation. 1996;98:2746–2755
  48. Mear JP, Schreiber KL, Munz C, et al. Misfolding of HLA-B27 as a result of its B pocket suggests a novel mechanism for its role in susceptibility to spondyloarthropathies. Journal of Immunology. 1999;163:6665–6670
  49. Popov I, Dela Cruz CS, Barber BH, et al. The effect of an anti-HLA-B27 immune response on CTL recognition of Chlamydia. Journal of Immunology. 2001;167:3375–3382
  50. Popov I, Dela Cruz CS, Barber BH, et al. Breakdown of CTL tolerance to self HLA-B*2705 induced by exposure to Chlamydia trachomatis. Journal of Immunology. 2002;169:4033–4038
  51. Colbert RA. HLA-B27 misfolding: a solution to the spondyloarthropathy conundrum?. Molecular Medicine Today. 2000;6:224–230
  52. Turner MJ, Sowders DP, DeLay ML, et al. HLA-B27 misfolding in transgenic rats is associated with activation of the unfolded protein response. Journal of Immunology. 2005;175:2438–2448
  53. Laivoranta S, Ilonen J, Tuokko J, et al. HLA frequencies in HLA-B27 negative patients with reactive arthritis. Clinical and Experimental Rheumatology. 1995;13:637–640
  54. Marker-Hermann E, Hohler T. Pathogenesis of human leukocyte antigen B27-positive arthritis. Information from clinical materials. Rheumatic Diseases Clinics of North America. 1998;24:865–881
  55. Braun J, Yin Z, Spiller I, et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis and Rheumatism. 1999;42:2039–2044
  56. Kaluza W, Leirisalo-Repo M, Marker-Hermann E, et al. IL10.G microsatellites mark promoter haplotypes associated with protection against the development of reactive arthritis in Finnish patients. Arthritis and Rheumatism. 2001;44:1209–1214
  57. Wang C, Tang J, Geisler WM, et al. Human leukocyte antigen and cytokine gene variants as predictors of recurrent Chlamydia trachomatis infection in high-risk adolescents. The Journal of Infectious Diseases. 2005;191:1084–1092
  58. Inman RD. Classification criteria for reactive arthritis. The Journal of Rheumatology. 1999;26:1219–1220
  59. Sieper J, Braun J. Problems and advances in the diagnosis of reactive arthritis. The Journal of Rheumatology. 1999;26:1222–1223
  60. Kuipers JG, Wollenhaupt J, Klos A, Zeidler H. Critical appraisal of molecular biological techniques for detecting bacteria in synovial specimens. Revue du Rhumatisme. 1999;66(supplement):3S–8S
  61. Flores D, Marquez J, Garza M, Espinoza LR. Reactive arthritis: newer developments. Rheumatic Diseases Clinics of North America. 2003;29:37–59
  62. Sieper J, Rudwaleit M, Braun J, van der Heijde D. Diagnosing reactive arthritis Role of clinical setting in the value of serologic and microbiologic assays. Arthritis and Rheumatism. 2002;46:319–327
  63. Haibel H, Rudwaleit M, Sieper J, et al. Diagnostik der reaktiven Arthritis. Zeitschrift für Rheumatologie. 2004;63:211–215
  64. Bardin T, Enel C, Cornelis F, et al. Antibiotic treatment of veneraeal disease and Reiter's syndrome in a Greenland population. Arthritis and Rheumatism. 1992;35:190–194
  65. Adimora AA. Treatment of uncomplicated genital Chlamydia trachomatis infection in adults. Clinical Infectious Diseases. 2002;35(supplement 2):S183–S186
  66. Colemegna I, Cuchacovich R, Espinoza LR. HLA-B27-associated reactive arthritis: pathogenetic and clinical considerations. Clinical Microbiology Reviews. 2004;17:348–369
  67. Köhler L, Kuipers JG, Zeidler H. Persistent chlamydial infections. Biomedical Progress. 2002;15:28–34
  68. Dreses-Werringloer U, Padubrin I, Zeidler H, Köhler L. Effect of azithromycin and rifampin on the infection of Chlamydia trachomatis in vitro. Antimicrobial Agents Chemotheraphy. 2001;45:3001–3008
  69. Carter JD, Valeriano J, Vasey FB. Doxycyclin versus doxycycline and rifampin in undifferentiated spondyloarthropathy, with special reference to Chlamydia-induced arthritis. A prospective, randomized 9-month comparison. Journal of Rheumatology. 2004;31:1973–1980
  70. Pavlica L, Nikolic D, Magic Z, et al. Successful treatment of postvenereal reactive arthritis with synovectomy and 3 months azithromycin. Journal of Clinical Rheumatology. 2005;11:257–263
  71. Laasila K, Laasonen L, Leirisalo-Repo M. Antibiotic treatment and long term prognosis of reactive arthritis. Annals of the Rheumatic Diseases. 2003;62:655–658
  72. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three month course of ciprofloxacin on the late prognosis of reactive arthritis. Annals of the Rheumatic Diseases. 2003;62:880–884
  73. Leirisalo-Repo . Reactive Arthritis. Scandinavian Journal of Rheumatology. 2005;34:251–259
  74. Koehler L, Kuipers JG, Zeidler H. Managing seronegative spondarthritides. Rheumatology. 2000;39:360–368
  75. Reveille JD, Arnett C. Spondyloarthritis: update on pathogensis and management. The American Journal of Medicine. 2005;118:592–603
  76. Anandarajah A, Ritchlin CT. Treatment update on spondyloarthropathy. Current Opinion in Rheumatology. 2005;17:247–256
  77. Clegg DO, Reda DJ, Weisman MH, et al. Henderson: Comparison of sulphasalzine and placebo in the treatment of reactive arthritis. Arthritis and Rheumatism. 1996;39:2021–2027
  78. Braun J, Sieper J. Biological therapies in the spondyloarthritides – the current state. Rheumatology. 2004;4:1072–1084
  79. Meador R, Hsia E, Kitumnuaypong T, Schumacher HR. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis. Clinical and Experimental Rheumatology. 2002;20(6 supplement 28):S130–S134
  80. Kaipiainen-Seppänen O, Niinisalo H, Korpilähde T, Virolainen J. Treatment of reactive arthritis with infliximab. Scandinavian Journal of Rheumatology. 2003;32:122–124
  81. Flagg SD, Meador R, Hsia E, Kitumnuaypong T, Schumacher HR. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial. Arthritis Care and Research. 2005;53:613–617
  82. Braun J, Davis J, Dougados M, et al. First update of the International ASAS Consensus Statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases. 2006;65:316–320[Epub 2005 Aug 11]
  83. Lauhio A, Leirisalo-Repo M, Lähdevirta J, et al. Double-blind, placebo-controlled study of three month treatment with lymecycline in reactive arthritis, with special reference to Chlamydia arthritis. Arthritis and Rheumatism. 1991;34:6–14
  84. Putschky N, Pott HG, Kuipers JG et al. A prospective, double-blind trial comparing ten-day versus four-month doxycycline in treatment of Chlamydia-induced reactive arthritis. Annals of the Rheumatic Diseases [in press].
  85. Smieja M, MacPherson DW, Kean W, et al. Randomised, blinded, placebo controlled trial of doxycycline for chronic seronegative arthritis. Annals of the Rheumatic Diseases. 2001;60:1088–1094
  86. Sieper J, Fendler C, Laitko S, et al. No benefit of long-term ciprofloxacin treatment in patients with reactive arthritis and undifferentiated oligoarthritis. Arthritis and Rheumatism. 1999;42:1386–1396
  87. Toivanen A, Yli-Kertulla T, Luukkainen R, et al. Effect of antimicrobial treatment on chronic reactive arthritis. Clinical and Experimental Rheumatology. 1993;11:301–307
  88. Wakefield D, McCluskey P, Verma M, et al. Ciprofloxacin treatment does not influence course or relapse rate of reactive arthritis and anterior uveitis. Arthritis and Rheumatism. 1999;42:1894–1897
  89. Yli-Kerttula T, Luukkainen R, Yli-Kerttula U, et al. Effect of a three month course of ciprofloxacin on the outcome of reactive arthritis. Annals of the Rheumatic Diseases. 2000;59:565–570
  90. Kvien TK, Gaston JSH, Bardin T, et al. Three-month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study. Annals of the Rheumatic Diseases. 2004;63:1113–1119

PII: S1521-6942(06)00112-4

doi: 10.1016/j.berh.2006.08.008

Best Practice & Research Clinical Rheumatology
Volume 20, Issue 6 , Pages 1119-1137 , December 2006

Article Tools

* Image Usage & Resolution